Muhammad Shuaib Abid
@shoaib9702.bsky.social
Interventional Cardiologist ,Multan,Pakistan🇵🇰
SoMA TCT,GulfPCR
SoMA TCT,GulfPCR
Pinned
November 1, 2025 at 8:59 AM
#TCT2025
TCT 2025 | October 28 | 11:00 AM Presentation PCI of Native Coronary Artery versus SVG in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR):
A Multicenter, Open-label, Randomized Trial
@crfheart
@TCT_ME_
@TCTConference
@aayshacader
TCT 2025 | October 28 | 11:00 AM Presentation PCI of Native Coronary Artery versus SVG in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR):
A Multicenter, Open-label, Randomized Trial
@crfheart
@TCT_ME_
@TCTConference
@aayshacader
September 25, 2025 at 3:04 PM
#TCT2025
TCT 2025 | October 28 | 11:00 AM Presentation PCI of Native Coronary Artery versus SVG in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR):
A Multicenter, Open-label, Randomized Trial
@crfheart
@TCT_ME_
@TCTConference
@aayshacader
TCT 2025 | October 28 | 11:00 AM Presentation PCI of Native Coronary Artery versus SVG in Patients with Prior Coronary Artery Bypass Graft Surgery (PROCTOR):
A Multicenter, Open-label, Randomized Trial
@crfheart
@TCT_ME_
@TCTConference
@aayshacader
Late Breaking RCT TCT 2025.
...........
1.SELUTION DeNovo:
Sirolimus DCB vs DES in de Novo lesions
2.SELUTION4ISR
Sirolimus DCB vs DES in ISR
3.Short-CUT
IVL vs CB in calcified lesions
4.VICTORY
IVL vs Super High pressure balloon in calcified lesions
5.PARTNER 3:
(7years outcome)
...........
1.SELUTION DeNovo:
Sirolimus DCB vs DES in de Novo lesions
2.SELUTION4ISR
Sirolimus DCB vs DES in ISR
3.Short-CUT
IVL vs CB in calcified lesions
4.VICTORY
IVL vs Super High pressure balloon in calcified lesions
5.PARTNER 3:
(7years outcome)
August 28, 2025 at 3:18 PM
Late Breaking RCT TCT 2025.
...........
1.SELUTION DeNovo:
Sirolimus DCB vs DES in de Novo lesions
2.SELUTION4ISR
Sirolimus DCB vs DES in ISR
3.Short-CUT
IVL vs CB in calcified lesions
4.VICTORY
IVL vs Super High pressure balloon in calcified lesions
5.PARTNER 3:
(7years outcome)
...........
1.SELUTION DeNovo:
Sirolimus DCB vs DES in de Novo lesions
2.SELUTION4ISR
Sirolimus DCB vs DES in ISR
3.Short-CUT
IVL vs CB in calcified lesions
4.VICTORY
IVL vs Super High pressure balloon in calcified lesions
5.PARTNER 3:
(7years outcome)
#TAVI
#NYValves2025
#APValves2025
Wires used for TAVI Crossing
3 commonly used wires are
1.Ampltaz
2.Confida
3.Safari
...
Name of all wires
▪︎Hightorque Supracore
▪︎ConfidaTMBrecker
.
▪︎Amplatz Family
▪︎Back up Meier TM wire
.
▪︎Lunderqvista extra stiff wire
.
▪︎Safari wires
#NYValves2025
#APValves2025
Wires used for TAVI Crossing
3 commonly used wires are
1.Ampltaz
2.Confida
3.Safari
...
Name of all wires
▪︎Hightorque Supracore
▪︎ConfidaTMBrecker
.
▪︎Amplatz Family
▪︎Back up Meier TM wire
.
▪︎Lunderqvista extra stiff wire
.
▪︎Safari wires
May 9, 2025 at 12:17 PM
#TAVI
#NYValves2025
#APValves2025
Wires used for TAVI Crossing
3 commonly used wires are
1.Ampltaz
2.Confida
3.Safari
...
Name of all wires
▪︎Hightorque Supracore
▪︎ConfidaTMBrecker
.
▪︎Amplatz Family
▪︎Back up Meier TM wire
.
▪︎Lunderqvista extra stiff wire
.
▪︎Safari wires
#NYValves2025
#APValves2025
Wires used for TAVI Crossing
3 commonly used wires are
1.Ampltaz
2.Confida
3.Safari
...
Name of all wires
▪︎Hightorque Supracore
▪︎ConfidaTMBrecker
.
▪︎Amplatz Family
▪︎Back up Meier TM wire
.
▪︎Lunderqvista extra stiff wire
.
▪︎Safari wires
#Mitra Clip was approved by FDA for
1.Primary MR based on #EVEREST II Trial in 2013
2.Secondary MR based on #COAPT Trial in 2019
@crfheart.bsky.social
@scainews.bsky.social
1.Primary MR based on #EVEREST II Trial in 2013
2.Secondary MR based on #COAPT Trial in 2019
@crfheart.bsky.social
@scainews.bsky.social
March 28, 2025 at 6:46 PM
#Mitra Clip was approved by FDA for
1.Primary MR based on #EVEREST II Trial in 2013
2.Secondary MR based on #COAPT Trial in 2019
@crfheart.bsky.social
@scainews.bsky.social
1.Primary MR based on #EVEREST II Trial in 2013
2.Secondary MR based on #COAPT Trial in 2019
@crfheart.bsky.social
@scainews.bsky.social
Alfieri stitch.(Bow-tie” or “Figure 8” procedure)
....
Dr Ottavio Alfieri ,an italian cardiothoracic surgeon first performed Surgical edge to edge repair of Mitral valve in 1991 for Symptomatic severe MR.He brought this idea after encountering a Pt with congenital double orifice.
#Cardiobird
....
Dr Ottavio Alfieri ,an italian cardiothoracic surgeon first performed Surgical edge to edge repair of Mitral valve in 1991 for Symptomatic severe MR.He brought this idea after encountering a Pt with congenital double orifice.
#Cardiobird
March 27, 2025 at 2:18 PM
Alfieri stitch.(Bow-tie” or “Figure 8” procedure)
....
Dr Ottavio Alfieri ,an italian cardiothoracic surgeon first performed Surgical edge to edge repair of Mitral valve in 1991 for Symptomatic severe MR.He brought this idea after encountering a Pt with congenital double orifice.
#Cardiobird
....
Dr Ottavio Alfieri ,an italian cardiothoracic surgeon first performed Surgical edge to edge repair of Mitral valve in 1991 for Symptomatic severe MR.He brought this idea after encountering a Pt with congenital double orifice.
#Cardiobird
When 2 branches r arising around ambiguous prox cap of occluded vessel, double side BASE technique can be used as a “move the cap” technique to facilitate extraplaque lesion crossing while preventing guidewire entry into the side branches & maintaining patency and access to side branches
February 22, 2025 at 8:12 AM
When 2 branches r arising around ambiguous prox cap of occluded vessel, double side BASE technique can be used as a “move the cap” technique to facilitate extraplaque lesion crossing while preventing guidewire entry into the side branches & maintaining patency and access to side branches
Classification of Athletes by Age .
1.Prepubertal athletes . (<12 years of age)
2. Adolescent athletes (middle and high school; 12 - 17 years of age)
3.Young adult athletes (college and professional (18-25 years )
4.Adult athletes ( 25 -35 years of age)
5.Masters athletes (>_ 35 years of age)
1.Prepubertal athletes . (<12 years of age)
2. Adolescent athletes (middle and high school; 12 - 17 years of age)
3.Young adult athletes (college and professional (18-25 years )
4.Adult athletes ( 25 -35 years of age)
5.Masters athletes (>_ 35 years of age)
February 21, 2025 at 1:36 PM
Classification of Athletes by Age .
1.Prepubertal athletes . (<12 years of age)
2. Adolescent athletes (middle and high school; 12 - 17 years of age)
3.Young adult athletes (college and professional (18-25 years )
4.Adult athletes ( 25 -35 years of age)
5.Masters athletes (>_ 35 years of age)
1.Prepubertal athletes . (<12 years of age)
2. Adolescent athletes (middle and high school; 12 - 17 years of age)
3.Young adult athletes (college and professional (18-25 years )
4.Adult athletes ( 25 -35 years of age)
5.Masters athletes (>_ 35 years of age)
February 12, 2025 at 2:03 PM
For Pt with Liver disease (Child pugh Class B)
& AFib requiring NOACS ,which agent is contraindicated
1.Apixaban
2.Dabigatran
3.Rivaroxaban
4.Edoxaban
& AFib requiring NOACS ,which agent is contraindicated
1.Apixaban
2.Dabigatran
3.Rivaroxaban
4.Edoxaban
January 17, 2025 at 4:56 PM
For Pt with Liver disease (Child pugh Class B)
& AFib requiring NOACS ,which agent is contraindicated
1.Apixaban
2.Dabigatran
3.Rivaroxaban
4.Edoxaban
& AFib requiring NOACS ,which agent is contraindicated
1.Apixaban
2.Dabigatran
3.Rivaroxaban
4.Edoxaban
January 14, 2025 at 5:11 PM
Treatment Modalities of ISR.
A.Basic Treatment.
1.DES
2.DCB
B.Adjunctive treatments.
1.Balloons based .
▪︎High Pressure NC
▪︎Scoring
▪︎Cutting
2.Waves based
▪︎IVL
▪︎Excimer Laser using ultraviolet rays
▪︎IVBT ( intravascular brachytherapy gamma & beta isotopes
3.Ablative therapies
A.Basic Treatment.
1.DES
2.DCB
B.Adjunctive treatments.
1.Balloons based .
▪︎High Pressure NC
▪︎Scoring
▪︎Cutting
2.Waves based
▪︎IVL
▪︎Excimer Laser using ultraviolet rays
▪︎IVBT ( intravascular brachytherapy gamma & beta isotopes
3.Ablative therapies
January 11, 2025 at 12:12 PM
Treatment Modalities of ISR.
A.Basic Treatment.
1.DES
2.DCB
B.Adjunctive treatments.
1.Balloons based .
▪︎High Pressure NC
▪︎Scoring
▪︎Cutting
2.Waves based
▪︎IVL
▪︎Excimer Laser using ultraviolet rays
▪︎IVBT ( intravascular brachytherapy gamma & beta isotopes
3.Ablative therapies
A.Basic Treatment.
1.DES
2.DCB
B.Adjunctive treatments.
1.Balloons based .
▪︎High Pressure NC
▪︎Scoring
▪︎Cutting
2.Waves based
▪︎IVL
▪︎Excimer Laser using ultraviolet rays
▪︎IVBT ( intravascular brachytherapy gamma & beta isotopes
3.Ablative therapies
●Angioseal is a collagen based vascular closure device
●Perclose Proglide is a suture based vascular closure device
●Perclose Proglide is a suture based vascular closure device
January 11, 2025 at 9:39 AM
●Angioseal is a collagen based vascular closure device
●Perclose Proglide is a suture based vascular closure device
●Perclose Proglide is a suture based vascular closure device
There r 2 Fascia Layers
1.Fascia Lata
2.Fascia Iliaca
Femoral Vein & Artery are located b/w Fascia Lata & Iliaca ,while Femoral Nerve is located more laterally belowFacia Iliaca .
If we inject near Femoral artery ,it will result inadequate analgesia due to barrier of fascia
.
December 21, 2024 at 6:47 PM
There r 2 Fascia Layers
1.Fascia Lata
2.Fascia Iliaca
Femoral Vein & Artery are located b/w Fascia Lata & Iliaca ,while Femoral Nerve is located more laterally belowFacia Iliaca .
If we inject near Femoral artery ,it will result inadequate analgesia due to barrier of fascia
.
Reposted by Muhammad Shuaib Abid
I’m excited to introduce our #AtheroTalk podcast! The first three episodes are live, and we’d love for you to tune in. Your feedback means the world to us—listen and share your thoughts!
#CardioSky #MedSky #Science #Podcast #atherosclerosis #ImmunoSky #EAS
open.spotify.com/show/2zYZmr7...
#CardioSky #MedSky #Science #Podcast #atherosclerosis #ImmunoSky #EAS
open.spotify.com/show/2zYZmr7...
AtheroTalk
Podcast · European Atherosclerosis Society · AtheroTalk is your go-to podcast for in-depth discussions on atherosclerosis and cardiovascular health. Join leading experts as they explore the latest res...
open.spotify.com
December 18, 2024 at 5:08 PM
I’m excited to introduce our #AtheroTalk podcast! The first three episodes are live, and we’d love for you to tune in. Your feedback means the world to us—listen and share your thoughts!
#CardioSky #MedSky #Science #Podcast #atherosclerosis #ImmunoSky #EAS
open.spotify.com/show/2zYZmr7...
#CardioSky #MedSky #Science #Podcast #atherosclerosis #ImmunoSky #EAS
open.spotify.com/show/2zYZmr7...
December 20, 2024 at 2:13 PM
HTN in Diabetics
#BPROAD trial showed that in patients with type 2 DM & HTN with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared with standard treatment targeting ≤140 mm Hg.
(SPRINT Trial was in Nondiabetics)
#BPROAD trial showed that in patients with type 2 DM & HTN with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared with standard treatment targeting ≤140 mm Hg.
(SPRINT Trial was in Nondiabetics)
December 15, 2024 at 8:39 AM
HTN in Diabetics
#BPROAD trial showed that in patients with type 2 DM & HTN with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared with standard treatment targeting ≤140 mm Hg.
(SPRINT Trial was in Nondiabetics)
#BPROAD trial showed that in patients with type 2 DM & HTN with elevated CV risk, intensive treatment targeting SBP ≤120 mm Hg reduced the incidence of MACE at 5 years compared with standard treatment targeting ≤140 mm Hg.
(SPRINT Trial was in Nondiabetics)
#HFpEF
#Obesity is main driver for HFpEF through visceral Adipose tissue & it leads to plasma volume expansion, as well as myocardial injury and fibrosis. In turn, this results in increased LV filling coupled with a decreased ability of the LV to tolerate that filling
(Obesity =HFpEF)
#Obesity is main driver for HFpEF through visceral Adipose tissue & it leads to plasma volume expansion, as well as myocardial injury and fibrosis. In turn, this results in increased LV filling coupled with a decreased ability of the LV to tolerate that filling
(Obesity =HFpEF)
December 14, 2024 at 6:25 PM
December 14, 2024 at 6:03 PM
#HFpEF
#AHA
Great news for obesity related Heart Failure .
Tirzepatide significantly cut risk of CV mortality and worsening heart failure events by 40% over a median follow-up of 2 years in patients with obesity and heart failure with preserved ejection (HFpEF) based on results of SUMMIT trial
#AHA
Great news for obesity related Heart Failure .
Tirzepatide significantly cut risk of CV mortality and worsening heart failure events by 40% over a median follow-up of 2 years in patients with obesity and heart failure with preserved ejection (HFpEF) based on results of SUMMIT trial
December 14, 2024 at 4:25 PM